Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dyne Therapeutics, Inc. (DYN)
USD23.76
-0.03 (-0.11%)
US NASDAQ S&P 500
Healthcare Biotechnology
Address
1560 Trapelo Road 2451
Waltham, MA, US
Waltham, MA, US
CEO
John G. Cox
Website
dyne-tx.com
IPO
2020-09-17
CIK 1818794 ISIN US26818M1080
Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2000-10-02 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD23.76
-0.03 (-0.11%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.08
Float Shares
129.40M
Free Float %
78.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49% | +5.09% | -3.32% | +18.21% | -2.44% | -6.08% | +51.82% | +34.19% | +8.19% | -23.14% | -23.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
23.76
Low
23.00
-3.2%
Consensus
37.60
+58.3%
Median
38.50
+62.1%
High
60.00
+152.6%
DCF (Unlevered)
6.74
-71.6%
DCF (Levered)
6.80
-71.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 11 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
42.50
+78.9%
|
| Last Year | 16 |
35.44
+49.2%
|
| All Time | 29 |
37.66
+58.5%
|
Quality scores
Altman Z-Score
5.88
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-3.0% Q1'26: +30.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+36.4% Q1'26: +50.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 10 EPS Ana. |
Dec 2027 8 Rev. Ana. 10 EPS Ana. |
Dec 2028 7 Rev. Ana. 9 EPS Ana. |
Dec 2029 3 Rev. Ana. 3 EPS Ana. |
Dec 2030 6 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 692.3K (-100.0%)
|
995.7K
178.9K – 3.11M
+43.8% YoY
|
61.97M
8.49M – 200.15M
+6,123.6% YoY
|
300.50M
54.00M – 937.39M
+384.9% YoY
|
852.23M
153.16M – 2.66B
+183.6% YoY
|
1.38B
248.44M – 4.31B
+62.2% YoY
|
| EBITDA |
-315.18M
|
-437.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-317.42M
|
-440.02M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-317.42M
est: -329.61M (+3.7%)
|
-446.21M
est: -446.21M (+0.0%)
|
-398.86M
-436.59M – -361.13M
+10.6% YoY
|
-339.97M
-445.86M – -234.08M
+14.8% YoY
|
-385.69M
-728.43M – 77.05M
-13.4% YoY
|
-36.25M
-136.13M – 2.41M
+90.6% YoY
|
285.46M
-18.95M – 1.07B
+887.5% YoY
|
| SGA |
62.48M
|
69.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.37
est: -3.47 (+2.8%)
|
-3.47
est: -3.50 (+0.9%)
|
-3.08
-3.40 – -2.81
+11.9% YoY
|
-2.97
-3.47 – -1.82
+3.6% YoY
|
-2.31
-5.67 – 0.60
+22.2% YoY
|
-0.28
-1.06 – 0.02
+87.8% YoY
|
2.22
-0.15 – 8.35
+887.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-188.16M
OE per share TTM
-3.16
Owner's Yield
-6.18%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,779.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
76
Total invested
336.22M
Insider transactions (90d)
15
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 9.03M | 8.99% | — | — | 9.03M | — | IN | Delaware | 2024-11-12 | ↗ |
| 2 | FMR LLC | 9.03M | 8.99% | 9.03M | — | 9.03M | — | HC | Delaware | 2024-11-12 | ↗ |
| 3 | (1) BlackRock, Inc. | 7.79M | 7.80% | 7.61M | — | — | 7.61M | HC | Delaware | 2024-11-08 | ↗ |
| 4 | RTW Investments, LP | 6.82M | 6.80% | — | 6.82M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 5 | Roderick Wong, M.D. | 6.82M | 6.80% | — | 6.82M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 6 | EIN #00-0000000 | 6.81M | 6.80% | — | 6.81M | — | 6.81M | IA, HC | Jersey, Channel Islands | 2024-11-14 | ↗ |
| 7 | Peter Kolchinsky | 5.21M | 6.40% | — | 5.21M | — | — | HC, IN | Delaware | 2024-04-04 | ↗ |
| 8 | RA Capital Healthcare Fund, L.P. | 5.21M | 6.40% | — | 5.21M | — | — | PN | Delaware | 2024-04-04 | ↗ |
| 9 | RA Capital Management, L.P. | 5.21M | 6.40% | — | 5.21M | — | — | IA, PN | Delaware | 2024-04-04 | ↗ |
| 10 | Rajeev Shah | 5.21M | 6.40% | — | 5.21M | — | — | HC, IN | United States | 2024-04-04 | ↗ |
| 11 | David Kroin | 4.50M | 5.55% | — | 4.50M | — | — | HC, IN | Delaware | 2024-01-19 | ↗ |
| 12 | Deep Track Biotechnology Master Fund, Ltd. | 4.50M | 5.55% | — | 4.50M | — | — | CO | Delaware | 2024-01-19 | ↗ |
| 13 | Deep Track Capital, LP | 4.50M | 5.55% | — | 4.50M | — | — | IA, OO | Delaware | 2024-01-19 | ↗ |
| 14 | Arsani William | 2.95M | 11.00% | — | 2.95M | — | 2.95M | HC, IN | — | 2022-02-14 | ↗ |
| 15 | Logos GP LLC | 2.95M | 11.00% | — | 2.95M | — | 2.95M | OO | — | 2022-02-14 | ↗ |
| 16 | Logos Global Management GP LLC | 2.95M | 11.00% | — | 2.95M | — | 2.95M | HC, OO | — | 2022-02-14 | ↗ |
| 17 | Logos Global Management LP | 2.95M | 11.00% | — | 2.95M | — | 2.95M | IA, PN | Delaware | 2022-02-14 | ↗ |
| 18 | Logos Global Master Fund LP | 2.15M | 11.00% | — | 2.15M | — | 2.15M | PN | Cayman Islands | 2022-02-14 | ↗ |
| 19 | 2. | 10.00 | 5.50% | — | 2.86M | — | — | HC, PN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
76
-164 vs prev Q
New positions
20
Closed positions
175
Increased
53
Reduced
14
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 17.54M +14.7M (+523.7%) | 343.09M +307.5M (+864.3%) | 12.37% +9.899 pp | 0.22% +0.195 pp | USD18.19 +7.5% | 4 qtrs — |
| 2 | JANUS HENDERSON GROUP PLC | 13.89M -857.8K (-5.8%) | 271.60M +85.1M (+45.6%) | 9.79% -3.156 pp | 0.12% +0.037 pp | USD21.06 -7.1% | 22 qtrs — |
| 3 | VANGUARD GROUP INC | 11.22M +1.5M (+14.9%) | 219.38M +95.9M (+77.7%) | 7.91% -0.663 pp | 0.00% +0.001 pp | USD22.24 -12.1% | 22 qtrs — |
| 4 | BLACKROCK, INC. | 11.19M +1.6M (+16.1%) | 218.89M +97.0M (+79.6%) | 7.89% -0.570 pp | 0.00% +0.002 pp | USD29.94 -34.7% | 6 qtrs — |
| 5 | ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | 9.13M +— (+0.0%) | 178.59M +63.1M (+54.6%) | 6.44% -1.580 pp | 20.64% +5.297 pp | USD11.69 +67.3% | 17 qtrs — |
| 6 | STATE STREET CORP | 6.69M +1.4M (+27.0%) | 130.91M +64.3M (+96.4%) | 4.72% +0.093 pp | 0.00% +0.002 pp | USD18.70 +4.6% | 21 qtrs — |
| 7 | FMR LLC | 6.57M +1.2M (+21.6%) | 128.51M +60.2M (+88.1%) | 4.63% -0.111 pp | 0.01% +0.003 pp | USD28.12 -30.4% | 17 qtrs — |
| 8 | FCPM III SERVICES B.V. | 5.46M +— (+0.0%) | 106.85M +37.7M (+54.6%) | 3.85% -0.945 pp | 14.01% +0.196 pp | USD16.51 +18.5% | 9 qtrs — |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.17M +1.6M (+45.5%) | 101.16M +56.2M (+125.0%) | 3.65% +0.526 pp | 0.15% +0.082 pp | USD12.88 +51.9% | 8 qtrs — |
| 10 | ORBIS ALLAN GRAY LTD | 4.80M +4.8M (+100.0%) | 93.93M +93.9M (+100.0%) | 3.39% +3.386 pp | 0.39% +0.394 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 11 | TCG CROSSOVER MANAGEMENT, LLC | 4.62M +— (+0.0%) | 90.27M +31.9M (+54.6%) | 3.25% -0.799 pp | 2.99% +0.116 pp | USD14.81 +32.1% | 12 qtrs — |
| 12 | JPMORGAN CHASE & CO | 3.55M +184.7K (+5.5%) | 69.44M +26.9M (+63.1%) | 2.50% -0.452 pp | 0.00% +0.002 pp | USD11.33 +72.6% | 21 qtrs — |
| 13 | SIREN, L.L.C. | 3.50M -1.2M (-25.9%) | 68.52M +8.7M (+14.5%) | 2.47% -1.683 pp | 2.04% -0.296 pp | USD16.60 +17.8% | 6 qtrs — |
| 14 | PERCEPTIVE ADVISORS LLC | 3.48M +2.9M (+543.7%) | 68.05M +61.2M (+895.3%) | 2.45% +1.979 pp | 1.21% +1.016 pp | USD19.08 +2.5% | 6 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 3.26M +395.8K (+13.8%) | 63.84M +27.6M (+76.0%) | 2.30% -0.217 pp | 0.00% +0.002 pp | USD19.61 -0.3% | 21 qtrs — |
| 16 | ARMISTICE CAPITAL, LLC | 3.25M +185.7K (+6.1%) | 63.56M +24.8M (+64.0%) | 2.29% -0.399 pp | 0.76% +0.181 pp | USD13.19 +48.3% | 11 qtrs — |
| 17 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 3.15M +435.0K (+16.0%) | 61.67M +27.3M (+79.4%) | 2.22% -0.164 pp | 1.66% +0.626 pp | USD12.54 +56.0% | 4 qtrs — |
| 18 | DEEP TRACK CAPITAL, LP | 2.65M +650.0K (+32.5%) | 51.83M +26.5M (+104.9%) | 1.87% +0.112 pp | 0.92% +0.218 pp | USD14.34 +36.4% | 17 qtrs — |
| 19 | VIVO CAPITAL, LLC | 2.61M +— (+0.0%) | 51.15M +18.1M (+54.6%) | 1.84% -0.452 pp | 3.31% +0.644 pp | USD15.43 +26.8% | 22 qtrs — |
| 20 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.32M +925.7K (+66.2%) | 45.45M +27.8M (+157.0%) | 1.64% +0.411 pp | 0.00% +0.003 pp | USD23.95 -18.3% | 18 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 2.28M +383.0K (+20.2%) | 44.66M +20.6M (+85.8%) | 1.61% -0.059 pp | 0.01% +0.003 pp | USD15.17 +28.9% | 22 qtrs — |
| 22 | SOFINNOVA INVESTMENTS, INC. | 2.25M +1.3M (+128.7%) | 44.09M +31.6M (+253.6%) | 1.59% +0.724 pp | 1.90% +1.219 pp | USD18.68 +4.7% | 11 qtrs — |
| 23 | ORBIMED ADVISORS LLC | 2.20M -112.0K (-4.8%) | 43.07M +13.8M (+47.1%) | 1.55% -0.479 pp | 0.88% +0.193 pp | USD18.53 +5.6% | 8 qtrs — |
| 24 | VR ADVISER, LLC | 2.17M +— (+0.0%) | 42.52M +15.0M (+54.6%) | 1.53% -0.376 pp | 2.10% +0.553 pp | USD11.25 +73.9% | 11 qtrs — |
| 25 | FRANKLIN RESOURCES INC | 2.01M +608.1K (+43.5%) | 39.25M +21.6M (+121.9%) | 1.42% +0.187 pp | 0.01% +0.005 pp | USD16.20 +20.7% | 22 qtrs — |
| 26 | SATURN V CAPITAL MANAGEMENT LLC | 1.79M -885.9K (-33.1%) | 34.99M +1.2M (+3.4%) | 1.26% -1.087 pp | 6.42% -0.999 pp | USD10.95 +78.6% | 3 qtrs — |
| 27 | SAMLYN CAPITAL, LLC | 1.49M +1.5M (+100.0%) | 29.20M +29.2M (+100.0%) | 1.05% +1.053 pp | 0.47% +0.465 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 28 | BRAIDWELL LP | 1.48M -1.3M (-45.9%) | 28.92M -5.6M (-16.3%) | 1.04% -1.355 pp | 0.92% -0.100 pp | USD12.92 +51.4% | 5 qtrs — |
| 29 | PALO ALTO INVESTORS LP | 1.47M +209.5K (+16.6%) | 28.80M +12.8M (+80.3%) | 1.04% -0.071 pp | 4.01% +1.053 pp | USD13.24 +47.7% | 4 qtrs — |
| 30 | BIOIMPACT CAPITAL LLC | 1.41M -41.0K (-2.8%) | 27.49M +9.2M (+50.2%) | 0.99% -0.279 pp | 3.15% +0.150 pp | USD9.52 +105.5% | 3 qtrs — |
| 31 | POLAR CAPITAL HOLDINGS PLC | 1.27M +739.7K (+139.7%) | 24.82M +18.1M (+270.7%) | 0.89% +0.430 pp | 0.10% +0.064 pp | USD16.68 +17.3% | 2 qtrs — |
| 32 | LOGOS GLOBAL MANAGEMENT LP | 1.25M -1.2M (-47.9%) | 24.45M -5.9M (-19.5%) | 0.88% -1.226 pp | 1.48% -1.244 pp | USD12.25 +59.7% | 22 qtrs — |
| 33 | MORGAN STANLEY | 1.21M -205.4K (-14.5%) | 23.74M +5.8M (+32.2%) | 0.86% -0.390 pp | 0.00% +0.000 pp | USD17.53 +11.6% | 21 qtrs — |
| 34 | CITADEL ADVISORS LLC | 1.17M -2.2M (-65.7%) | 22.92M -20.3M (-46.9%) | 0.83% -2.171 pp | 0.00% -0.003 pp | USD14.89 +31.4% | 22 qtrs — |
| 35 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.15M +144.1K (+14.3%) | 22.52M +9.8M (+76.8%) | 0.81% -0.073 pp | 0.00% +0.002 pp | USD19.51 +0.3% | 21 qtrs — |
| 36 | FRONTIER CAPITAL MANAGEMENT CO LLC | 1.14M +227.9K (+25.0%) | 22.28M +10.8M (+93.3%) | 0.80% +0.003 pp | 0.24% +0.133 pp | USD15.43 +26.8% | 5 qtrs — |
| 37 | ABRDN PLC | 1.11M +551.4K (+99.0%) | 21.68M +14.6M (+207.8%) | 0.78% +0.293 pp | 0.03% +0.022 pp | USD15.29 +27.9% | 7 qtrs — |
| 38 | NORTHERN TRUST CORP | 1.09M +54.6K (+5.3%) | 21.36M +8.2M (+62.8%) | 0.77% -0.141 pp | 0.00% +0.001 pp | USD19.71 -0.8% | 21 qtrs — |
| 39 | CANDRIAM S.C.A. | 1.06M +223.3K (+26.8%) | 20.68M +10.1M (+96.0%) | 0.75% +0.013 pp | 0.10% +0.048 pp | USD14.81 +32.1% | 19 qtrs — |
| 40 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 913.0K +88.9K (+10.8%) | 17.86M +7.4M (+71.3%) | 0.64% -0.080 pp | 0.92% +0.307 pp | USD21.00 -6.9% | 8 qtrs — |
| 41 | MILLENNIUM MANAGEMENT LLC | 904.4K +490.4K (+118.5%) | 17.69M +12.5M (+237.8%) | 0.64% +0.274 pp | 0.01% +0.005 pp | USD16.61 +17.8% | 9 qtrs — |
| 42 | BANK OF AMERICA CORP /DE/ | 882.9K +121.8K (+16.0%) | 17.27M +7.6M (+79.4%) | 0.62% -0.046 pp | 0.00% +0.001 pp | USD14.72 +32.9% | 21 qtrs — |
| 43 | STEMPOINT CAPITAL LP | 835.2K +360.6K (+76.0%) | 16.34M +10.3M (+172.1%) | 0.59% +0.172 pp | 2.80% +1.598 pp | USD15.63 +25.1% | 4 qtrs — |
| 44 | BAKER BROS. ADVISORS LP | 813.4K +813.4K (+100.0%) | 15.91M +15.9M (+100.0%) | 0.57% +0.574 pp | 0.09% +0.093 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 45 | ARROWMARK COLORADO HOLDINGS LLC | 700.7K -85.3K (-10.8%) | 13.70M +3.8M (+37.8%) | 0.49% -0.196 pp | 0.30% +0.117 pp | USD26.86 -27.2% | 22 qtrs — |
| 46 | EVENTIDE ASSET MANAGEMENT, LLC | 680.3K +680.3K (+100.0%) | 13.31M +13.3M (+100.0%) | 0.48% +0.480 pp | 0.21% +0.208 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 47 | MARSHALL WACE, LLP | 677.0K -2.3M (-77.5%) | 13.24M -24.9M (-65.3%) | 0.48% -2.169 pp | 0.01% -0.027 pp | USD12.18 +60.6% | 19 qtrs — |
| 48 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 649.7K +649.7K (+100.0%) | 12.71M +12.7M (+100.0%) | 0.46% +0.458 pp | 0.02% +0.019 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 49 | NUVEEN, LLC | 621.3K +276.4K (+80.1%) | 12.15M +7.8M (+178.5%) | 0.44% +0.135 pp | 0.00% +0.002 pp | USD15.02 +30.2% | 4 qtrs — |
| 50 | RAYMOND JAMES FINANCIAL INC | 530.3K +453.4K (+589.5%) | 10.37M +9.4M (+966.2%) | 0.37% +0.306 pp | 0.00% +0.003 pp | USD19.62 -0.3% | 5 qtrs — |
| 51 | CATALIO CAPITAL MANAGEMENT, LP | 519.7K +519.7K (+100.0%) | 10.17M +10.2M (+100.0%) | 0.37% +0.367 pp | 1.80% +1.797 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 52 | ENSIGN PEAK ADVISORS, INC | 496.6K +476.4K (+2,364.5%) | 9.71M +9.5M (+3,710.7%) | 0.35% +0.333 pp | 0.02% +0.017 pp | USD19.17 +2.0% | 22 qtrs — |
| 53 | RENAISSANCE TECHNOLOGIES LLC | 470.6K +125.1K (+36.2%) | 9.21M +4.8M (+110.6%) | 0.33% +0.029 pp | 0.01% +0.009 pp | USD14.49 +35.0% | 2 qtrs — |
| 54 | FEDERATED HERMES, INC. | 464.8K +464.8K (+100.0%) | 9.09M +9.1M (+100.0%) | 0.33% +0.328 pp | 0.02% +0.015 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 55 | BARCLAYS PLC | 448.7K +241.3K (+116.4%) | 8.78M +1.3M (+17.9%) | 0.32% +0.134 pp | 0.00% +0.000 pp | USD19.69 -0.7% | 16 qtrs — |
| 56 | BALYASNY ASSET MANAGEMENT L.P. | 433.0K +433.0K (+100.0%) | 8.47M +8.5M (+100.0%) | 0.31% +0.305 pp | 0.01% +0.011 pp | USD19.56 +0.0% | 6 qtrs — |
| 57 | TD ASSET MANAGEMENT INC | 419.8K +399.4K (+1,959.4%) | 8.21M +8.0M (+3,084.4%) | 0.30% +0.278 pp | 0.01% +0.006 pp | USD19.22 +1.8% | 12 qtrs — |
| 58 | UNIVERSITY OF WISCONSIN FOUNDATION | 416.8K -101.0K (-19.5%) | 8.15M +1.6M (+24.5%) | 0.29% -0.161 pp | 6.85% +1.308 pp | USD12.65 +54.6% | 2 qtrs — |
| 59 | QUBE RESEARCH & TECHNOLOGIES LTD | 412.4K -417.3K (-50.3%) | 8.07M -2.4M (-23.1%) | 0.29% -0.438 pp | 0.01% -0.003 pp | USD15.00 +30.4% | 9 qtrs — |
| 60 | CLEARBRIDGE INVESTMENTS, LLC | 407.8K +407.8K (+100.0%) | 7.98M +8.0M (+100.0%) | 0.29% +0.288 pp | 0.01% +0.006 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 61 | WASATCH ADVISORS LP | 407.0K -117.0K (-22.3%) | 7.96M +1.3M (+20.1%) | 0.29% -0.173 pp | 0.05% +0.012 pp | USD11.52 +69.8% | 14 qtrs — |
| 62 | SPHERA FUNDS MANAGEMENT LTD. | 392.9K -33.6K (-7.9%) | 7.69M +2.3M (+42.4%) | 0.28% -0.098 pp | 1.49% +0.348 pp | USD17.49 +11.8% | 6 qtrs — |
| 63 | UBS GROUP AG | 381.0K +31.6K (+9.0%) | 7.45M +3.0M (+68.6%) | 0.27% -0.038 pp | 0.00% +0.001 pp | USD18.69 +4.7% | 17 qtrs — |
| 64 | SCHRODER INVESTMENT MANAGEMENT GROUP | 387.0K +111.4K (+40.4%) | 7.43M +4.0M (+117.9%) | 0.27% +0.031 pp | 0.01% +0.003 pp | USD15.81 +23.7% | 9 qtrs — |
| 65 | BANK OF NEW YORK MELLON CORP | 353.5K +36.1K (+11.4%) | 6.91M +2.9M (+72.2%) | 0.25% -0.029 pp | 0.00% +0.001 pp | USD20.74 -5.7% | 22 qtrs — |
| 66 | Y-INTERCEPT (HONG KONG) LTD | 343.7K +343.7K (+100.0%) | 6.72M +6.7M (+100.0%) | 0.24% +0.242 pp | 0.15% +0.150 pp | USD19.56 +0.0% | 6 qtrs — |
| 67 | POINT72 ASSET MANAGEMENT, L.P. | 329.3K -1.4M (-80.8%) | 6.44M -15.3M (-70.4%) | 0.23% -1.276 pp | 0.01% -0.029 pp | USD13.04 +50.0% | 22 qtrs — |
| 68 | CANADA PENSION PLAN INVESTMENT BOARD | 284.0K +— (+0.0%) | 5.56M +2.0M (+54.6%) | 0.20% -0.049 pp | 0.00% +0.001 pp | USD12.65 +54.6% | 2 qtrs — |
| 69 | ALGERT GLOBAL LLC | 271.3K -243.8K (-47.3%) | 5.31M -1.2M (-18.6%) | 0.19% -0.261 pp | 0.08% -0.026 pp | USD12.98 +50.7% | 15 qtrs — |
| 70 | SG AMERICAS SECURITIES, LLC | 265.4K +265.4K (+100.0%) | 5.19M +5.2M (+100.0%) | 0.19% +0.187 pp | 0.01% +0.007 pp | USD19.56 +0.0% | 9 qtrs — |
| 71 | SQUAREPOINT OPS LLC | 255.2K +207.6K (+436.1%) | 4.99M +4.4M (+729.0%) | 0.18% +0.138 pp | 0.01% +0.005 pp | USD18.64 +4.9% | 8 qtrs — |
| 72 | FISHER ASSET MANAGEMENT, LLC | 250.1K +250.1K (+100.0%) | 4.89M +4.9M (+100.0%) | 0.18% +0.176 pp | 0.00% +0.002 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 73 | TFG ASSET MANAGEMENT GP LTD | 248.0K +24.8K (+11.1%) | 4.85M +2.0M (+71.8%) | 0.17% -0.021 pp | 1.02% +0.645 pp | USD11.59 +68.8% | 3 qtrs — |
| 74 | SUMMITTX CAPITAL, L.P. | 243.3K +110.4K (+83.1%) | 4.76M +3.1M (+183.0%) | 0.17% +0.055 pp | 0.14% +0.074 pp | USD14.71 +33.0% | 4 qtrs — |
| 75 | NEO IVY CAPITAL MANAGEMENT | 237.5K +237.5K (+100.0%) | 4.64M +4.6M (+100.0%) | 0.17% +0.168 pp | 0.73% +0.734 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 76 | RAFFERTY ASSET MANAGEMENT, LLC | 233.8K +20.6K (+9.7%) | 4.57M +1.9M (+69.6%) | 0.16% -0.022 pp | 0.02% +0.007 pp | USD17.64 +10.9% | 14 qtrs — |
| 77 | RUSSELL INVESTMENTS GROUP, LTD. | 232.0K +118.1K (+103.6%) | 4.54M +3.1M (+214.9%) | 0.16% +0.064 pp | 0.00% +0.003 pp | USD16.69 +17.2% | 14 qtrs — |
| 78 | SWISS NATIONAL BANK | 222.5K +44.2K (+24.8%) | 4.35M +2.1M (+93.0%) | 0.16% +0.000 pp | 0.00% +0.001 pp | USD19.01 +2.9% | 19 qtrs — |
| 79 | UBS ASSET MANAGEMENT AMERICAS INC | 214.5K -14.9K (-6.5%) | 4.20M +1.3M (+44.6%) | 0.15% -0.050 pp | 0.00% +0.000 pp | USD19.94 -1.9% | 18 qtrs — |
| 80 | AMERIPRISE FINANCIAL INC | 197.7K -225.0K (-53.2%) | 3.87M -1.5M (-27.7%) | 0.14% -0.232 pp | 0.00% 0.000 pp | USD23.26 -15.9% | 7 qtrs — |
| 81 | DEUTSCHE BANK AG\ | 196.1K +70.2K (+55.8%) | 3.84M +2.2M (+140.8%) | 0.14% +0.028 pp | 0.00% +0.001 pp | USD15.83 +23.6% | 21 qtrs — |
| 82 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 195.0K +105.7K (+118.4%) | 3.81M +2.7M (+237.6%) | 0.14% +0.059 pp | 0.00% +0.000 pp | USD17.78 +10.0% | 11 qtrs — |
| 83 | PDT PARTNERS, LLC | 183.0K -18.3K (-9.1%) | 3.58M +1.0M (+40.6%) | 0.13% -0.048 pp | 0.23% +0.072 pp | USD10.07 +94.2% | 4 qtrs — |
| 84 | RHUMBLINE ADVISERS | 175.0K +7.2K (+4.3%) | 3.42M +1.3M (+61.3%) | 0.12% -0.024 pp | 0.00% +0.001 pp | USD19.03 +2.8% | 20 qtrs — |
| 85 | AMERICAN CENTURY COMPANIES INC | 168.3K +136.9K (+436.3%) | 3.29M +2.9M (+729.2%) | 0.12% +0.091 pp | 0.00% +0.002 pp | USD18.27 +7.1% | 2 qtrs — |
| 86 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 165.7K +164.8K (+19,485.3%) | 3.24M +3.2M (+29,363.6%) | 0.12% +0.116 pp | 0.00% +0.004 pp | USD19.51 +0.3% | 3 qtrs — |
| 87 | NEUBERGER BERMAN GROUP LLC | 165.5K -155.9K (-48.5%) | 3.24M -829.2K (-20.4%) | 0.12% -0.166 pp | 0.00% -0.001 pp | USD10.70 +82.8% | 6 qtrs — |
| 88 | JAIN GLOBAL LLC | 162.0K -482.0K (-74.8%) | 3.17M -5.0M (-61.1%) | 0.11% -0.451 pp | 0.02% -0.023 pp | USD9.75 +100.6% | 3 qtrs — |
| 89 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 158.0K +98.7K (+166.4%) | 3.09M +2.3M (+311.9%) | 0.11% +0.059 pp | 0.03% +0.030 pp | USD16.67 +17.3% | 7 qtrs — |
| 90 | FIRST LIGHT ASSET MANAGEMENT, LLC | 155.2K +155.2K (+100.0%) | 3.04M +3.0M (+100.0%) | 0.11% +0.110 pp | 0.23% +0.232 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 91 | BURKEHILL GLOBAL MANAGEMENT, LP | 155.0K +35.0K (+29.2%) | 3.03M +1.5M (+99.7%) | 0.11% +0.004 pp | 0.20% +0.113 pp | USD14.21 +37.6% | 2 qtrs — |
| 92 | LISANTI CAPITAL GROWTH, LLC | 154.4K +154.4K (+100.0%) | 3.02M +3.0M (+100.0%) | 0.11% +0.109 pp | 0.72% +0.716 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 93 | WELLS FARGO & COMPANY/MN | 147.8K +60.7K (+69.7%) | 2.89M +1.8M (+162.4%) | 0.10% +0.028 pp | 0.00% +0.000 pp | USD17.61 +11.1% | 21 qtrs — |
| 94 | TUDOR INVESTMENT CORP ET AL | 147.6K +147.6K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.10% +0.104 pp | 0.01% +0.005 pp | USD19.56 +0.0% | 1 qtrs NEW |
| 95 | INVESCO LTD. | 137.7K +20.1K (+17.1%) | 2.69M +1.2M (+81.1%) | 0.10% -0.006 pp | 0.00% +0.000 pp | USD16.07 +21.7% | 19 qtrs — |
| 96 | ALLIANCEBERNSTEIN L.P. | 134.3K +27.6K (+25.9%) | 2.63M +1.3M (+94.6%) | 0.09% +0.001 pp | 0.00% +0.000 pp | USD18.04 +8.4% | 16 qtrs — |
| 97 | JANE STREET GROUP, LLC | 122.2K +57.0K (+87.4%) | 2.39M +1.6M (+189.8%) | 0.09% +0.029 pp | 0.00% +0.000 pp | USD14.40 +35.8% | 3 qtrs — |
| 98 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 120.8K +31.6K (+35.5%) | 2.36M +1.2M (+109.5%) | 0.09% +0.007 pp | 0.00% +0.001 pp | USD17.50 +11.8% | 21 qtrs — |
| 99 | WOODLINE PARTNERS LP | 120.8K +120.8K (+100.0%) | 2.36M +2.4M (+100.0%) | 0.09% +0.085 pp | 0.01% +0.009 pp | USD19.56 +0.0% | 11 qtrs — |
| 100 | VESTAL POINT CAPITAL, LP | 120.0K -2.7M (-95.7%) | 2.35M -32.8M (-93.3%) | 0.08% -2.352 pp | 0.08% -1.505 pp | USD12.08 +61.9% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 108 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 1.98% | 4.21M | 0.50% |
| 2 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 1.00% | 224.1K | 0.45% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.90% | 323.7K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.90% | 97.51M | 0.35% |
| 5 | Virtus Biotech Clinical Trials ETF BBC | 0.79% | 456.2K | 0.65% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.27% | 1.23M | 0.40% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.27% | 198.9K | 0.19% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.27% | 195.0K | 0.35% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.27% | 2.91M | 0.35% |
| 10 | Optimize Strategy Index ETF OPTZ | 0.26% | 629.1K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
57
Shares acquired
—
Shares disposed
2.06M
Cash buys
—
Cash sales
56.00
Net activity
-2,060,076
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 43,621 | 18.18 | 793.0K | 4,883,494 | I | ↗ |
| 2026-05-05 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 6,081 | 18.03 | 109.6K | 4,927,115 | I | ↗ |
| 2026-05-04 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 6,241 | 18.00 | 112.3K | 4,933,196 | I | ↗ |
| 2026-04-28 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 26 | 19.00 | 494.00 | 1,577,406 | I | ↗ |
| 2026-04-27 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 45,709 | 18.15 | 829.6K | 1,637,302 | I | ↗ |
| 2026-04-24 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 710 | 18.48 | 13.1K | 10,576 | I | ↗ |
| 2026-04-24 | Lubner David Charles | Director | G-Gift | D | Common Stock | 53,625 | 0.00 | — | 0 | D | ↗ |
| 2026-04-23 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 15,148 | 19.19 | 290.7K | 1,270,556 | I | ↗ |
| 2026-04-22 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 150,942 | 19.68 | 2.97M | 5,260,179 | I | ↗ |
| 2026-04-22 | Kersten Dirk | Director | S-Sale | D | Common Stock | 2,652 | 20.00 | 53.0K | 4,196,573 | I | ↗ |
| 2026-04-21 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 142,253 | 19.51 | 2.78M | 5,412,651 | I | ↗ |
| 2026-04-21 | Kersten Dirk | Director | S-Sale | D | Common Stock | 8,300 | 20.01 | 166.1K | 4,199,225 | I | ↗ |
| 2026-04-20 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 56,368 | 20.06 | 1.13M | 1,402,200 | I | ↗ |
| 2026-04-20 | Kersten Dirk | Director | S-Sale | D | Common Stock | 125,274 | 20.07 | 2.51M | 4,207,525 | I | ↗ |
| 2026-04-17 | Kersten Dirk | Director | S-Sale | D | Common Stock | 211,974 | 20.29 | 4.30M | 4,332,799 | I | ↗ |
| 2026-04-16 | Kersten Dirk | Director | S-Sale | D | Common Stock | 11,116 | 21.10 | 234.6K | 4,551,430 | I | ↗ |
| 2026-04-15 | Kersten Dirk | Director | S-Sale | D | Common Stock | 81,840 | 20.27 | 1.66M | 4,562,546 | I | ↗ |
| 2026-04-01 | Lucera Erick | Officer | S-Sale | D | Common Stock | 5,727 | 18.64 | 106.8K | 125,373 | D | ↗ |
| 2026-03-30 | Posner Brian S | Director | P-Purchase | A | Common Stock | 2,000 | 17.08 | 34.2K | 15,500 | D | ↗ |
| 2026-03-11 | Posner Brian S | Director | P-Purchase | A | Common Stock | 2,000 | 19.35 | 38.7K | 13,500 | D | ↗ |
| 2026-03-11 | Kersten Dirk | Director | S-Sale | D | Common Stock | 129,672 | 19.52 | 2.53M | 4,644,386 | I | ↗ |
| 2026-03-10 | Kersten Dirk | Director | S-Sale | D | Common Stock | 9,482 | 18.21 | 172.7K | 5,275,674 | I | ↗ |
| 2026-03-09 | Kersten Dirk | Director | S-Sale | D | Common Stock | 177,690 | 17.72 | 3.15M | 5,285,156 | I | ↗ |
| 2026-03-06 | Posner Brian S | Director | P-Purchase | A | Common Stock | 3,000 | 15.06 | 45.2K | 11,500 | D | ↗ |
| 2026-03-05 | Kerr Douglas | Officer | S-Sale | D | Common Stock | 904 | 14.90 | 13.5K | 171,606 | D | ↗ |
| 2026-03-05 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 148 | 14.90 | 2.2K | 154,581 | D | ↗ |
| 2026-03-05 | Cox John | Director / Officer | S-Sale | D | Common Stock | 2,732 | 14.90 | 40.7K | 374,145 | D | ↗ |
| 2026-02-12 | Lucera Erick | Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 131,100 | D | ↗ |
| 2026-02-12 | Kerr Douglas | Officer | A-Award | A | Common Stock | 85,000 | 0.00 | — | 172,510 | D | ↗ |
| 2026-02-12 | Friedl-Naderer Johanna | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 154,729 | D | ↗ |
| 2026-02-12 | Cox John | Director / Officer | A-Award | A | Common Stock | 180,000 | 0.00 | — | 376,877 | D | ↗ |
| 2025-12-22 | Karnani Vikram | Director | A-Award | A | Stock option (right to buy) | 59,665 | 20.78 | 1.24M | 59,665 | D | ↗ |
| 2025-12-05 | Kerr Douglas | Officer | S-Sale | D | Common Stock | 880 | 20.72 | 18.2K | 87,510 | D | ↗ |
| 2025-12-05 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 144 | 20.72 | 3.0K | 94,729 | D | ↗ |
| 2025-12-05 | Cox John | Director / Officer | S-Sale | D | Common Stock | 2,662 | 20.72 | 55.2K | 196,877 | D | ↗ |
| 2025-10-01 | Posner Brian S | Director | A-Award | A | Stock option (right to buy) | 70,000 | 12.50 | 875.0K | 70,000 | D | ↗ |
| 2025-09-05 | Kerr Douglas | Officer | S-Sale | D | Common Stock | 873 | 13.41 | 11.7K | 88,390 | D | ↗ |
| 2025-09-05 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 144 | 13.41 | 1.9K | 94,873 | D | ↗ |
| 2025-09-05 | Cox John | Director / Officer | S-Sale | D | Common Stock | 2,640 | 13.41 | 35.4K | 199,539 | D | ↗ |
| 2025-09-04 | Kerr Douglas | Officer | S-Sale | D | Common Stock | 3,552 | 13.27 | 47.1K | 89,263 | D | ↗ |
| 2025-09-04 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 894 | 13.27 | 11.9K | 95,017 | D | ↗ |
| 2025-07-16 | Kerr Douglas | Officer | A-Award | A | Stock option (right to buy) | 65,110 | 9.33 | 607.5K | 65,110 | D | ↗ |
| 2025-07-16 | Friedl-Naderer Johanna | Officer | A-Award | A | Stock option (right to buy) | 51,255 | 9.33 | 478.2K | 51,255 | D | ↗ |
| 2025-07-16 | Cox John | Director / Officer | A-Award | A | Stock option (right to buy) | 197,285 | 9.33 | 1.84M | 197,285 | D | ↗ |
| 2025-07-15 | Cox John | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 232,179 | D | ↗ |
| 2025-07-14 | Cox John | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 9.11 | 911.0K | 242,179 | D | ↗ |
| 2025-06-05 | Kerr Douglas | Officer | S-Sale | D | Common Stock | 1,342 | 13.35 | 17.9K | 92,815 | D | ↗ |
| 2025-06-05 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 146 | 13.35 | 1.9K | 95,911 | D | ↗ |
| 2025-06-05 | Cox John | Director / Officer | S-Sale | D | Common Stock | 4,060 | 13.35 | 54.2K | 142,179 | D | ↗ |
| 2025-05-30 | Stehman-Breen Catherine | Director | A-Award | A | Stock option (right to buy) | 35,000 | 11.96 | 418.6K | 35,000 | D | ↗ |
| 2025-05-30 | Rhodes Jason P | Director | A-Award | A | Stock option (right to buy) | 35,000 | 11.96 | 418.6K | 35,000 | D | ↗ |
| 2025-05-30 | Lubner David Charles | Director | A-Award | A | Stock option (right to buy) | 35,000 | 11.96 | 418.6K | 35,000 | D | ↗ |
| 2025-05-30 | Kersten Dirk | Director | A-Award | A | Stock option (right to buy) | 35,000 | 11.96 | 418.6K | 35,000 | D | ↗ |
| 2025-05-30 | Incerti Carlo | Director | A-Award | A | Stock option (right to buy) | 35,000 | 11.96 | 418.6K | 35,000 | D | ↗ |
| 2025-05-30 | HURWITZ EDWARD | Director | A-Award | A | Stock option (right to buy) | 35,000 | 11.96 | 418.6K | 35,000 | D | ↗ |
| 2025-03-31 | Lucera Erick | Officer | A-Award | A | Common Stock | 66,100 | 0.00 | — | 66,100 | D | ↗ |
| 2025-03-13 | Friedl-Naderer Johanna | Officer | S-Sale | D | Common Stock | 143 | 12.12 | 1.7K | 96,057 | D | ↗ |
| 2025-03-11 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,343 | 11.38 | 15.3K | 122,330 | D | ↗ |
| 2025-03-11 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,153 | 11.38 | 24.5K | 195,840 | D | ↗ |
| 2025-03-05 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 917 | 11.83 | 10.8K | 123,673 | D | ↗ |
| 2025-03-05 | Kerr Douglas | Officer | S-Sale | D | Common Stock | 1,343 | 11.83 | 15.9K | 94,157 | D | ↗ |
| 2025-03-05 | Cox John | Director / Officer | S-Sale | D | Common Stock | 4,061 | 11.83 | 48.0K | 146,239 | D | ↗ |
| 2025-03-05 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 1,094 | 11.83 | 12.9K | 197,993 | D | ↗ |
| 2025-02-18 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 2,488 | 13.95 | 34.7K | 124,590 | D | ↗ |
| 2025-02-18 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,598 | 13.95 | 36.2K | 199,087 | D | ↗ |
| 2025-01-27 | Rhodes Jason P | Director | A-Award | A | Common Stock | 1,111,111 | 13.50 | 15.00M | 1,958,427 | I | ↗ |
| 2024-12-11 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,455 | 28.12 | 40.9K | 127,078 | D | ↗ |
| 2024-12-11 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,334 | 28.12 | 65.6K | 201,685 | D | ↗ |
| 2024-12-09 | Kersten Dirk | Director | S-Sale | D | Common Stock | 34,437 | 29.18 | 1.00M | 5,400,545 | I | ↗ |
| 2024-12-06 | Kersten Dirk | Director | S-Sale | D | Common Stock | 101,675 | 29.34 | 2.98M | 5,434,982 | I | ↗ |
| 2024-12-05 | Kersten Dirk | Director | S-Sale | D | Common Stock | 3,806 | 29.05 | 110.6K | 5,536,657 | I | ↗ |
| 2024-12-04 | Scalzo Richard William | Officer | A-Award | A | Stock option (right to buy) | 52,300 | 29.44 | 1.54M | 52,300 | D | ↗ |
| 2024-12-04 | Kersten Dirk | Director | S-Sale | D | Common Stock | 135,039 | 29.39 | 3.97M | 5,540,463 | I | ↗ |
| 2024-12-04 | Kerr Douglas | Officer | A-Award | A | Stock option (right to buy) | 76,600 | 29.44 | 2.26M | 76,600 | D | ↗ |
| 2024-12-04 | Friedl-Naderer Johanna | Officer | A-Award | A | Stock option (right to buy) | 60,300 | 29.44 | 1.78M | 60,300 | D | ↗ |
| 2024-12-04 | Cox John | Director / Officer | A-Award | A | Common Stock | 145,300 | 0.00 | — | 150,300 | D | ↗ |
| 2024-12-04 | Beskrovnaya Oxana | Officer | A-Award | A | Common Stock | 27,400 | 0.00 | — | 204,019 | D | ↗ |
| 2024-12-03 | Kersten Dirk | Director | S-Sale | D | Common Stock | 29,732 | 29.05 | 863.7K | 5,675,502 | I | ↗ |
| 2024-12-02 | Kersten Dirk | Director | S-Sale | D | Common Stock | 79,973 | 29.66 | 2.37M | 5,706,462 | I | ↗ |
| 2024-11-18 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 2,735 | 28.20 | 77.1K | 95,833 | D | ↗ |
| 2024-11-18 | Incerti Carlo | Director | S-Sale | D | Common Stock | 16,500 | 28.73 | 474.0K | 0 | D | ↗ |
| 2024-11-18 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,856 | 28.20 | 80.5K | 137,519 | D | ↗ |
| 2024-11-14 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 583 | 33.10 | 19.3K | 5,697,508 | I | ↗ |
| 2024-11-14 | Kersten Dirk | Director | S-Sale | D | Common Stock | 8,929 | 32.82 | 293.0K | 5,786,435 | I | ↗ |
| 2024-11-13 | Kersten Dirk | Director | S-Sale | D | Common Stock | 10,803 | 35.24 | 380.7K | 62,301 | I | ↗ |
| 2024-10-21 | Kersten Dirk | Director | S-Sale | D | Common Stock | 121 | 35.06 | 4.2K | 73,104 | I | ↗ |
| 2024-10-18 | Kersten Dirk | Director | S-Sale | D | Common Stock | 13,414 | 35.16 | 471.6K | 73,225 | I | ↗ |
| 2024-10-17 | Kersten Dirk | Director | S-Sale | D | Common Stock | 13,013 | 35.17 | 457.7K | 86,639 | I | ↗ |
| 2024-10-16 | Kersten Dirk | Director | S-Sale | D | Common Stock | 23,671 | 35.35 | 836.8K | 99,652 | I | ↗ |
| 2024-10-02 | Kersten Dirk | Director | S-Sale | D | Common Stock | 21,518 | 35.38 | 761.3K | 128,764 | I | ↗ |
| 2024-10-01 | Kersten Dirk | Director | S-Sale | D | Common Stock | 8,423 | 35.16 | 296.2K | 150,282 | I | ↗ |
| 2024-09-30 | Kersten Dirk | Director | S-Sale | D | Common Stock | 29,007 | 35.47 | 1.03M | 160,640 | I | ↗ |
| 2024-09-27 | Kersten Dirk | Director | S-Sale | D | Common Stock | 32 | 35.00 | 1.1K | 189,647 | I | ↗ |
| 2024-09-26 | Kersten Dirk | Director | S-Sale | D | Common Stock | 1,260 | 35.29 | 44.5K | 189,679 | I | ↗ |
| 2024-09-25 | Kersten Dirk | Director | S-Sale | D | Common Stock | 2,357 | 35.06 | 82.6K | 190,939 | I | ↗ |
| 2024-09-23 | Kersten Dirk | Director | S-Sale | D | Common Stock | 4,610 | 36.33 | 167.5K | 193,296 | I | ↗ |
| 2024-09-20 | Kersten Dirk | Director | S-Sale | D | Common Stock | 78,940 | 36.45 | 2.88M | 234,598 | I | ↗ |
| 2024-09-19 | Kersten Dirk | Director | S-Sale | D | Common Stock | 27,767 | 35.74 | 992.4K | 364,510 | I | ↗ |
| 2024-09-18 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,390 | 34.55 | 48.0K | 98,568 | — | ↗ |
| 2024-09-18 | Kersten Dirk | Director | S-Sale | D | Common Stock | 1,554 | 35.03 | 54.4K | 392,277 | I | ↗ |
| 2024-09-18 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 4,636 | 34.41 | 159.5K | 131,636 | — | ↗ |
| 2024-09-18 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,339 | 34.55 | 80.8K | 140,375 | — | ↗ |
| 2024-09-17 | Kersten Dirk | Director | S-Sale | D | Common Stock | 3,272 | 35.13 | 114.9K | 393,831 | — | ↗ |
| 2024-09-16 | Kersten Dirk | Director | S-Sale | D | Common Stock | 1,320 | 35.04 | 46.3K | 397,103 | — | ↗ |
| 2024-09-11 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,468 | 31.89 | 46.8K | 99,958 | — | ↗ |
| 2024-09-11 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 2,548 | 31.89 | 81.3K | 143,334 | — | ↗ |
| 2024-09-11 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,161 | 31.89 | 68.9K | 142,714 | — | ↗ |
| 2024-09-06 | Scalzo Richard William | Officer | M-Exempt | D | Stock option (right to buy) | 29,792 | 8.58 | 255.6K | 25,208 | — | ↗ |
| 2024-09-05 | Kersten Dirk | Director | S-Sale | D | Common Stock | 1,577 | 35.03 | 55.2K | 398,423 | — | ↗ |
| 2024-09-04 | Cox John | Director / Officer | P-Purchase | A | Common Stock | 7,200 | 33.09 | 238.2K | 8,000 | — | ↗ |
| 2024-09-03 | Kerr Douglas | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-03 | Friedl-Naderer Johanna | Officer | A-Award | A | Stock Option (Right to Buy) | 185,300 | 31.94 | 5.92M | 185,300 | — | ↗ |
| 2024-08-30 | Kersten Dirk | Director | S-Sale | D | Common Stock | 6,204 | 46.01 | 285.4K | 400,000 | — | ↗ |
| 2024-08-29 | Kersten Dirk | Director | S-Sale | D | Common Stock | 45,640 | 45.19 | 2.06M | 442,068 | — | ↗ |
| 2024-08-28 | Kersten Dirk | Director | S-Sale | D | Common Stock | 16,386 | 44.41 | 727.7K | 549,175 | — | ↗ |
| 2024-08-27 | Kersten Dirk | Director | S-Sale | D | Common Stock | 65,403 | 44.28 | 2.90M | 565,561 | — | ↗ |
| 2024-08-26 | Kersten Dirk | Director | S-Sale | D | Common Stock | 11,534 | 45.79 | 528.1K | 630,964 | — | ↗ |
| 2024-08-23 | Kersten Dirk | Director | S-Sale | D | Common Stock | 20,955 | 45.82 | 960.2K | 784,594 | — | ↗ |
| 2024-08-22 | Kersten Dirk | Director | S-Sale | D | Common Stock | 94,908 | 45.82 | 4.35M | 805,962 | — | ↗ |
| 2024-08-21 | Kersten Dirk | Director | S-Sale | D | Common Stock | 64,518 | 46.52 | 3.00M | 972,115 | — | ↗ |
| 2024-08-20 | Kersten Dirk | Director | S-Sale | D | Common Stock | 43,057 | 45.68 | 1.97M | 1,080,416 | — | ↗ |
| 2024-08-19 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 2,442 | 45.01 | 109.9K | 111,332 | — | ↗ |
| 2024-08-19 | McNeill Jonathan | Officer | S-Sale | D | Common Stock | 305 | 46.00 | 14.0K | 132,106 | — | ↗ |
| 2024-08-19 | Kersten Dirk | Director | S-Sale | D | Common Stock | 30,448 | 45.10 | 1.37M | 1,219,057 | — | ↗ |
| 2024-08-19 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 2,582 | 45.01 | 116.2K | 146,210 | — | ↗ |
| 2024-08-19 | Farwell Wildon | Officer | S-Sale | D | Common Stock | 261 | 46.00 | 12.0K | 143,222 | — | ↗ |
| 2024-08-19 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 296 | 46.00 | 13.6K | 144,875 | — | ↗ |
| 2024-08-16 | Kersten Dirk | Director | S-Sale | D | Common Stock | 34,485 | 44.52 | 1.54M | 1,337,663 | — | ↗ |
| 2024-08-15 | Kersten Dirk | Director | S-Sale | D | Common Stock | 131,290 | 45.25 | 5.94M | 1,421,749 | — | ↗ |
| 2024-08-14 | Kersten Dirk | Director | S-Sale | D | Common Stock | 100,650 | 43.67 | 4.40M | 1,553,039 | — | ↗ |
| 2024-08-13 | Kersten Dirk | Director | S-Sale | D | Common Stock | 24,378 | 42.08 | 1.03M | 1,763,296 | — | ↗ |
| 2024-08-12 | Kersten Dirk | Director | S-Sale | D | Common Stock | 26,416 | 42.74 | 1.13M | 1,839,750 | — | ↗ |
| 2024-08-09 | Kersten Dirk | Director | S-Sale | D | Common Stock | 40,268 | 43.44 | 1.75M | 1,867,326 | — | ↗ |
| 2024-08-08 | Kersten Dirk | Director | S-Sale | D | Common Stock | 68,936 | 42.87 | 2.96M | 1,958,330 | — | ↗ |
| 2024-06-24 | HIGH SUSANNA GATTI | Officer | M-Exempt | D | Stock option (right to buy) | 10,163 | 5.54 | 56.3K | 60,536 | — | ↗ |
| 2024-06-21 | HIGH SUSANNA GATTI | Officer | M-Exempt | D | Stock option (right to buy) | 29,787 | 5.54 | 165.0K | 70,699 | — | ↗ |
| 2024-06-12 | HIGH SUSANNA GATTI | Officer | M-Exempt | A | Common Stock | 40,000 | 5.54 | 221.6K | 188,792 | — | ↗ |
| 2024-06-11 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,331 | 31.34 | 41.7K | 113,774 | — | ↗ |
| 2024-06-11 | McNeill Jonathan | Officer | S-Sale | D | Common Stock | 1,823 | 31.34 | 57.1K | 134,811 | — | ↗ |
| 2024-06-11 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 2,357 | 31.23 | 73.6K | 151,705 | — | ↗ |
| 2024-06-11 | Farwell Wildon | Officer | S-Sale | D | Common Stock | 1,628 | 31.27 | 50.9K | 146,551 | — | ↗ |
| 2024-06-11 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,136 | 31.34 | 66.9K | 147,511 | — | ↗ |
| 2024-06-10 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,590 | 30.23 | 48.1K | 115,105 | — | ↗ |
| 2024-06-10 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 80,000 | 30.24 | 2.42M | 154,062 | — | ↗ |
| 2024-05-22 | Stehman-Breen Catherine | Director | A-Award | A | Stock option (right to buy) | 25,133 | 31.53 | 792.4K | 25,133 | — | ↗ |
| 2024-05-22 | Rhodes Jason P | Director | A-Award | A | Stock option (right to buy) | 25,133 | 31.53 | 792.4K | 25,133 | — | ↗ |
| 2024-05-22 | Lubner David Charles | Director | A-Award | A | Stock option (right to buy) | 25,133 | 31.53 | 792.4K | 25,133 | — | ↗ |
| 2024-05-22 | Kersten Dirk | Director | A-Award | A | Stock option (right to buy) | 25,133 | 31.53 | 792.4K | 25,133 | — | ↗ |
| 2024-05-22 | Incerti Carlo | Director | A-Award | A | Stock option (right to buy) | 25,133 | 31.53 | 792.4K | 25,133 | — | ↗ |
| 2024-05-22 | HURWITZ EDWARD | Director | A-Award | A | Stock option (right to buy) | 25,133 | 31.53 | 792.4K | 25,133 | — | ↗ |
| 2024-05-20 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 12,147 | 33.51 | 407.0K | 150,792 | — | ↗ |
| 2024-05-16 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 462 | 28.59 | 13.2K | 116,695 | — | ↗ |
| 2024-05-16 | McNeill Jonathan | Officer | S-Sale | D | Common Stock | 495 | 28.59 | 14.2K | 136,634 | — | ↗ |
| 2024-05-16 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 2,249 | 28.20 | 63.4K | 154,551 | — | ↗ |
| 2024-05-16 | Farwell Wildon | Officer | S-Sale | D | Common Stock | 1,956 | 28.20 | 55.2K | 148,604 | — | ↗ |
| 2024-05-16 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 483 | 28.59 | 13.8K | 149,647 | — | ↗ |
| 2024-03-25 | Cox John | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2024-03-12 | Farwell Wildon | Officer | S-Sale | D | Common Stock | 1,030 | 25.58 | 26.3K | 150,560 | — | ↗ |
| 2024-03-11 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 1,082 | 25.70 | 27.8K | 120,873 | — | ↗ |
| 2024-03-11 | McNeill Jonathan | Officer | S-Sale | D | Common Stock | 1,776 | 25.71 | 45.7K | 139,408 | — | ↗ |
| 2024-03-11 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 2,292 | 25.70 | 58.9K | 156,800 | — | ↗ |
| 2024-03-11 | Farwell Wildon | Officer | S-Sale | D | Common Stock | 1,585 | 25.70 | 40.7K | 151,590 | — | ↗ |
| 2024-03-11 | Brumm Joshua T | Director / Officer | M-Exempt | A | Common Stock | 50,000 | 5.54 | 277.0K | 604,385 | — | ↗ |
| 2024-03-11 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,081 | 25.70 | 53.5K | 152,352 | — | ↗ |
| 2024-03-08 | Scalzo Richard William | Officer | M-Exempt | D | Stock option (right to buy) | 68,919 | 5.54 | 381.8K | 9,855 | — | ↗ |
| 2024-03-08 | McNeill Jonathan | Officer | M-Exempt | D | Stock option (right to buy) | 86,159 | 5.54 | 477.3K | 12,309 | — | ↗ |
| 2024-03-08 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 26,908 | 26.66 | 717.4K | 159,383 | — | ↗ |
| 2024-03-08 | Brumm Joshua T | Director / Officer | S-Sale | D | Common Stock | 202,238 | 25.30 | 5.12M | 715,490 | — | ↗ |
| 2024-03-07 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 2,273 | 25.85 | 58.8K | 121,955 | — | ↗ |
| 2024-03-07 | McNeill Jonathan | Officer | S-Sale | D | Common Stock | 2,434 | 25.85 | 62.9K | 141,184 | — | ↗ |
| 2024-03-07 | HIGH SUSANNA GATTI | Officer | S-Sale | D | Common Stock | 1,591 | 25.85 | 41.1K | 186,291 | — | ↗ |
| 2024-03-07 | Farwell Wildon | Officer | S-Sale | D | Common Stock | 8,364 | 25.80 | 215.8K | 154,732 | — | ↗ |
| 2024-03-07 | Brumm Joshua T | Director / Officer | S-Sale | D | Common Stock | 9,086 | 25.85 | 234.9K | 554,385 | — | ↗ |
| 2024-03-07 | Beskrovnaya Oxana | Officer | S-Sale | D | Common Stock | 2,373 | 25.85 | 61.3K | 154,433 | — | ↗ |
| 2024-03-01 | Scalzo Richard William | Officer | S-Sale | D | Common Stock | 564 | 28.65 | 16.2K | 124,228 | — | ↗ |
| 2024-03-01 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 17,099 | 30.05 | 513.8K | 847,388 | — | ↗ |
| 2024-03-01 | McNeill Jonathan | Officer | M-Exempt | D | Stock option (right to buy) | 24,260 | 0.73 | 17.7K | 0 | — | ↗ |
| 2024-03-01 | Brumm Joshua T | Director / Officer | S-Sale | D | Common Stock | 1,414 | 29.70 | 42.0K | 563,471 | — | ↗ |
| 2024-03-01 | Atlas Venture Opportunity Fund I, L.P. | 10% Owner | S-Sale | D | Common Stock | 17,099 | 30.05 | 513.8K | 847,388 | — | ↗ |
| 2024-02-29 | Scalzo Richard William | Officer | M-Exempt | D | Stock option (right to buy) | 3,429 | 1.03 | 3.5K | 9,311 | — | ↗ |
| 2024-02-29 | McNeill Jonathan | Officer | M-Exempt | D | Stock option (right to buy) | 4,268 | 0.73 | 3.1K | 24,260 | — | ↗ |
| 2024-02-29 | Brumm Joshua T | Director / Officer | S-Sale | D | Common Stock | 5,520 | 27.50 | 151.8K | 563,471 | — | ↗ |
| 2024-02-28 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 22,567 | 24.83 | 560.3K | 1,488,486 | — | ↗ |
| 2024-02-28 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 210 | 25.25 | 5.3K | 864,487 | — | ↗ |
| 2024-02-27 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 40,455 | 24.38 | 986.3K | 1,514,874 | — | ↗ |
| 2024-02-27 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 272,923 | 24.38 | 6.65M | 5,878,544 | — | ↗ |
| 2024-02-26 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 136,312 | 23.59 | 3.22M | 6,216,250 | — | ↗ |
| 2024-02-26 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 64,783 | 23.98 | 1.55M | 6,151,467 | — | ↗ |
| 2024-02-23 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 159,542 | 22.70 | 3.62M | 6,352,562 | — | ↗ |
| 2024-02-23 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 13,738 | 22.70 | 311.9K | 920,843 | — | ↗ |
| 2024-02-22 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 119,360 | 22.66 | 2.70M | 6,512,104 | — | ↗ |
| 2024-02-22 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 119,360 | 22.66 | 2.70M | 6,512,104 | — | ↗ |
| 2024-02-21 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 35,164 | 23.14 | 813.7K | 6,631,464 | — | ↗ |
| 2024-02-21 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 35,164 | 23.14 | 813.7K | 6,631,464 | — | ↗ |
| 2024-02-20 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 166,029 | 22.71 | 3.77M | 6,819,475 | — | ↗ |
| 2024-02-20 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 166,029 | 22.71 | 3.77M | 6,819,475 | — | ↗ |
| 2024-02-16 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 162,707 | 23.14 | 3.77M | 6,985,504 | — | ↗ |
| 2024-02-16 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 162,707 | 23.14 | 3.77M | 6,985,504 | — | ↗ |
| 2024-02-15 | Rhodes Jason P | Director | S-Sale | D | Common Stock | 175,793 | 23.88 | 4.20M | 7,150,324 | — | ↗ |
| 2024-02-15 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 175,793 | 23.88 | 4.20M | 7,150,324 | — | ↗ |
Executive team
Top executives
Shares Outstanding
165.22M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Erick Lucera | 392.0K | — | 691.4K | 1.41M | 197.6K | 6.8K | 2.70M | 77.88% | ↗ |
| 2 | 2025 | John G. Cox President and Chief Executive Officer | 721.0K | — | — | 937.9K | 411.0K | 7.0K | 2.08M | 45.16% | ↗ |
| 3 | 2025 | Johanna Friedl-Naderer Chief Commercial Officer | 610.7K | — | — | 243.7K | 232.1K | — | 1.09M | 22.43% | ↗ |
| 4 | 2025 | Douglas Kerr Chief Medical Officer | 537.0K | — | — | 309.5K | 204.1K | 7.0K | 1.06M | 29.27% | ↗ |
| 5 | 2025 | Oxana Beskrovnaya Chief Innovation Officer; Former Chief Scientific Officer | 531.5K | — | — | 252.2K | 202.0K | 7.0K | 992.6K | 25.40% | ↗ |
| 6 | 2025 | Richard Scalzo Former Senior Vice President, Head of Finance and Administration | 107.5K | — | 166.8K | 106.3K | — | 347.0K | 727.6K | 37.53% | ↗ |
| 7 | 2024 | John G. Cox President and Chief Executive Officer | 537.0K | — | 4.28M | 15.53M | 339.5K | 796.00 | 20.69M | 95.76% | ↗ |
| 8 | 2024 | John G. Cox President and Chief Executive Officer | 537.0K | — | 4.28M | 15.53M | 339.5K | 796.00 | 20.69M | 95.76% | ↗ |
| 9 | 2024 | Josh Brumm Former President and Chief Executive Officer | 156.0K | — | 10.51M | 3.19M | — | 523.5K | 14.38M | 95.28% | ↗ |
| 10 | 2024 | Johanna Friedl-Naderer Chief Commercial Officer | 171.2K | — | 2.98M | 4.81M | 231.0K | — | 8.19M | 95.09% | ↗ |
| 11 | 2024 | Johanna Friedl-Naderer Chief Commercial Officer | 171.2K | — | 2.98M | 4.81M | 231.0K | — | 8.19M | 95.09% | ↗ |
| 12 | 2024 | Douglas Kerr Chief Medical Officer | 172.8K | — | 2.93M | 4.42M | 222.6K | 335.00 | 7.74M | 94.89% | ↗ |
| 13 | 2024 | Douglas Kerr Chief Medical Officer | 172.8K | — | 2.93M | 4.42M | 222.6K | 335.00 | 7.74M | 94.89% | ↗ |
| 14 | 2024 | Oxana Beskrovnaya Chief Scientific Officer | 506.0K | — | 1.96M | 1.16M | 212.5K | 1.0K | 3.84M | 81.24% | ↗ |
| 15 | 2024 | Oxana Beskrovnaya Chief Innovation Officer; Former Chief Scientific Officer | 506.0K | — | 1.96M | 1.16M | 212.5K | 1.0K | 3.84M | 81.24% | ↗ |
| 16 | 2024 | Richard Scalzo Former Senior Vice President, Head of Finance and Administration | 403.0K | — | 962.7K | 970.9K | 148.1K | 1.0K | 2.49M | 77.79% | ↗ |
| 17 | 2024 | Richard Scalzo Former Senior Vice President, Head of Finance and Administration | 403.0K | — | 962.7K | 970.9K | 148.1K | 1.0K | 2.49M | 77.79% | ↗ |
| 18 | 2023 | Josh Brumm Former President and Chief Executive Officer | 643.6K | — | 3.90M | 965.2K | 460.1K | 996.00 | 5.97M | 81.51% | ↗ |
| 19 | 2023 | Jonathan McNeill Chief Business Officer | 430.5K | — | 1.05M | 522.3K | 230.9K | 996.00 | 2.23M | 70.31% | ↗ |
| 20 | 2023 | Susanna High Chief Operating Officer | 497.9K | — | 1.03M | 255.2K | 258.9K | 996.00 | 2.05M | 62.95% | ↗ |
| 21 | 2023 | Oxana Beskrovnaya Chief Innovation Officer; Former Chief Scientific Officer | 477.1K | — | 1.02M | 252.1K | 248.1K | 996.00 | 2.00M | 63.65% | ↗ |
| 22 | 2023 | Oxana Beskrovnaya Chief Scientific Officer | 477.1K | — | 1.02M | 252.1K | 248.1K | 996.00 | 2.00M | 63.65% | ↗ |
| 23 | 2022 | Josh Brumm Former President and Chief Executive Officer | 610.0K | — | 1.71M | 1.66M | 335.5K | 996.00 | 4.32M | 78.08% | ↗ |
| 24 | 2022 | Joshua Brumm President and Chief Executive Officer | 610.0K | — | 1.71M | 1.66M | 335.5K | 996.00 | 4.32M | 78.08% | ↗ |
| 25 | 2022 | Susanna High Chief Operating Officer | 467.5K | — | 471.7K | 467.1K | 187.0K | 996.00 | 1.59M | 58.88% | ↗ |
| 26 | 2022 | Oxana Beskrovnaya Chief Scientific Officer | 450.1K | — | 428.8K | 426.5K | 180.0K | 996.00 | 1.49M | 57.54% | ↗ |
| 27 | 2021 | Joshua Brumm President and Chief Executive Officer | 562.0K | — | 1.55M | 1.51M | 451.8K | 13.0K | 4.09M | 74.87% | ↗ |
| 28 | 2021 | Oxana Beskrovnaya Chief Scientific Officer | 406.9K | — | 1.82M | 479.2K | 201.5K | 1.0K | 2.91M | 79.05% | ↗ |
| 29 | 2021 | Susanna High Chief Operating Officer | 425.0K | — | 514.8K | 528.9K | 221.0K | 926.00 | 1.69M | 61.73% | ↗ |
| 30 | 2020 | Joshua Brumm President and Chief Executive Officer | 482.7K | — | 3.13M | 7.94M | 299.9K | 6.9K | 11.87M | 93.35% | ↗ |
| 31 | 2020 | Romesh Subramanian, Ph.D. Chief Scientific Officer | 371.9K | — | 987.3K | 2.82M | 186.4K | 6.9K | 4.37M | 87.07% | ↗ |
| 32 | 2020 | Susanna High Chief Operating Officer | 167.8K | — | 858.1K | 2.65M | 73.3K | 418.00 | 3.75M | 93.55% | ↗ |
| 33 | 2019 | Romesh Subramanian, Ph.D. Chief Scientific Officer | 350.0K | — | — | — | 61.3K | 408.00 | 411.7K | 0.00% | ↗ |
| 34 | 2019 | Joshua Brumm President and Chief Executive Officer | 97.2K | 180.0K | — | — | — | 102.00 | 277.3K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John G. Cox | Chief Executive Officer, President & Director | 1M | male |
| Johanna Friedl-Naderer | Chief Commercial Officer | 842.8K | female |
| Douglas Kerr | Chief Medical Officer | 748.1K | — |
| Oxana Beskrovnaya | Chief Innovation Officer | 740.5K | — |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | 726.9K | male |
| Vikram Ranade | Chief Business Officer | 662.3K | male |
| James Bilotta | Chief Digital & Information Officer | — | male |
| Debra Feldman | Chief Regulatory Affairs Officer | — | female |
| Jose Juves | Chief Corporate & Patient Affairs Officer | — | male |
| Lucia Celona | Chief Human Resource Officer | — | female |
| Monica Fay | Chief Medical Affairs Officer | — | female |
| Daniel Wilson | Senior Vice President & Head of Legal | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DYN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
